Search clinical trials for: 177Lu-DOTA-HH1

Total 383 results

Wanbangde Pharmaceutical Group Co., LTD
The First Affiliated Hospital, Guangzhou University of Traditional Chinese...

Unknown

The Efficacy and Safety of Ginkgo Biloba Dropping Pills in the Treatment of Coronary Heart Disease With Stable Angina Pectoris and Depression

Stable Angina Pectoris Associated With Depression

China
Dana-Farber Cancer Institute
Novartis

Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

Meningioma

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Breast Cancer

Spain, Singapore
Novartis Pharmaceuticals

Active, not recruiting

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)

Prostatic Neoplasms

Belgium, Canada, Spain, Germany, Austria, Netherlands, United Kingdom, United States, France, Switzerland, Sweden, Slovakia, Poland, Czechia
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Novartis Pharmaceuticals

Completed

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Breast Cancer | Lung Cancer

United States
ITM Solucin GmbH

Recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

Neuroendocrine Tumors

United States, United Kingdom, Australia, Netherlands, France, Italy, Spain, Germany, Sweden, India
Lund University Hospital

Active, not recruiting

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (START-NET)

Neuroendocrine Tumors

Sweden
Lale Kostakoglu

Terminated

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
National Cancer Centre, Singapore
Novartis; Advanced Accelerator Applications

Recruiting

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in (SG-AAA-II-01)

Metastatic Nasopharyngeal Cancer

Singapore
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
University Hospital, Basel, Switzerland
University Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaborators

Completed

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

Thyroid Cancer, Medullary

Switzerland
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

Germany, France, Spain, Portugal, Poland
Wuhan Union Hospital, China

Recruiting

Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors

Malignant Neoplasm

China
Imperial College London

Not yet recruiting

Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS)

Neuroendocrine Tumors
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
Stony Brook University

Terminated

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention (STATUS PCI)

Coronary Artery Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Bone Metastases | Lung Metastases | HER2-positive Breast Cancer | Liver Metastases | Stage IV Breast Cancer | Recurrent Breast Cancer | Soft Tissue Metastases

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Wisconsin, Madison

Not yet recruiting

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine Tumors | Somatostatin Receptor-positive Neuroendocrine Tumor

United States
M.D. Anderson Cancer Center
Telix Pharmaceuticals Limited

Active, not recruiting

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Clear Cell Renal Cell Carcinoma | Advanced Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Sandeep Laroia
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Terminated

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Neuroendocrine Tumors

United States
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma

United States
Gilead Sciences
National Cancer Institute (NCI)

Withdrawn

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Emory University

Completed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Timothy M. Bateman, MD

Completed

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

Myocardial Blood Flow Reserve

United States
Stanford University

Completed

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

Diagnostic Imaging | Cancer Diagnosis | Diagnostic Techniques and Procedures

United States
Cancer Targeted Technology
National Cancer Institute (NCI); University of California, San Francisco

Completed

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Paola Anna Erba
Erasmus Medical Center; Jagiellonian University; Medical University Innsbruck; University... and other collaborators

Completed

Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC (GRAN-T-MTC)

Medullary Thyroid Carcinoma

Austria, Germany, Netherlands, Poland, Slovenia
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; Advanced Accelerator Applications

Recruiting

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM)

Pancreatic Neuroendocrine Carcinoma

France
Andrei Iagaru
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Prostate Cancer

United States
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
Central Hospital, Nancy, France

Not yet recruiting

Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial (ELUMEN)

Meningioma

France
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
Sue O'Dorisio
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Dosimetry Guided PRRT With 90Y-DOTATOC

Medulloblastoma | Neuroblastoma | Meningioma | Neuroendrocrine Tumors
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Locally Advanced Rectal Carcinoma

United States
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China

Search clinical trials for: 177Lu-DOTA-HH1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations